Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
melanoma
Pharma
BMS’ Opdualag flunks trial as adjuvant for resected melanoma
BMS revealed that a phase 3 trial of Opdualag in patients with completely resected stage III/IV melanoma did not achieve its primary endpoint.
Kevin Dunleavy
Feb 14, 2025 8:15am
Ideaya hires Gilead leader to head up commercialization push
Nov 19, 2024 10:34am
Castle Biosciences taps ‘Real Housewife’ for melanoma awareness
Jul 23, 2024 12:23pm
ASCO: BMS' triplet, Iovance's Amtagvi-Keytruda target melanoma
May 23, 2024 5:00pm
FDA approves first T-cell therapy for a solid tumor
Feb 17, 2024 12:15pm
BMS's Opdivo claims more of the melanoma pie
Oct 16, 2023 11:06am